Review of checkpoint immunotherapy for the management of non-small cell lung cancer
Shine Raju,1 Ranjit Joseph,2 Sameep Sehgal3 1Division of Geriatrics and Palliative Care, Case Western University, Cleveland, OH, USA; 2Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC, USA; 3Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine,...
Main Authors: | Raju S, Joseph R, Sehgal S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-07-01
|
Series: | ImmunoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/review-of-checkpoint-immunotherapy-for-the-management-of-non-small-cel-peer-reviewed-article-ITT |
Similar Items
-
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01) -
Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01) -
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01) -
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
by: Qingyuan Huang, et al.
Published: (2018-12-01) -
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)